Add to ORKGDPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rat
Cardiovascular diseases frequently coexist with chronic kidney disease that constitutes a major dete...
This study was performed to assess the effect of chronic low-dose sitagliptin, a dipeptidyl peptidas...
The purpose of this paper is to evaluate the chronic effect of sitagliptin on metabolic profile, inf...
This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibit...
Background/Aims: Dipeptidyl peptidase-4 (DPP4) inhibitors are known to have a protective effect on d...
Objective: This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-...
Dipeptidyl peptidase IV (DPPIV) inhibitors are antidiabetic agents that exert renoprotective actions...
Heart failure with preserved ejection fraction (HFpEF) is a systemic syndrome driven by co-morbiditi...
Background. Previous studies have shown the antiapoptotic and anti-inflammatory potential of DPP-IV ...
The incidence of chronic kidney disease (CKD) in Type 2 Diabetes Mellitus patients accounts for 34,6...
Background : The inhibition of dipeptidyl peptidase (DPP) IV shows protective effects on tissue inju...
Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal disease (ESRD) worldw...
The goal of this study was to investigate the possible protective effects of sitagliptin against dys...
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral anti-diabetic drugs, implicated in ple...
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral anti-diabetic drugs, implicated in ple...
Cardiovascular diseases frequently coexist with chronic kidney disease that constitutes a major dete...
This study was performed to assess the effect of chronic low-dose sitagliptin, a dipeptidyl peptidas...
The purpose of this paper is to evaluate the chronic effect of sitagliptin on metabolic profile, inf...
This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibit...
Background/Aims: Dipeptidyl peptidase-4 (DPP4) inhibitors are known to have a protective effect on d...
Objective: This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-...
Dipeptidyl peptidase IV (DPPIV) inhibitors are antidiabetic agents that exert renoprotective actions...
Heart failure with preserved ejection fraction (HFpEF) is a systemic syndrome driven by co-morbiditi...
Background. Previous studies have shown the antiapoptotic and anti-inflammatory potential of DPP-IV ...
The incidence of chronic kidney disease (CKD) in Type 2 Diabetes Mellitus patients accounts for 34,6...
Background : The inhibition of dipeptidyl peptidase (DPP) IV shows protective effects on tissue inju...
Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal disease (ESRD) worldw...
The goal of this study was to investigate the possible protective effects of sitagliptin against dys...
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral anti-diabetic drugs, implicated in ple...
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral anti-diabetic drugs, implicated in ple...
Cardiovascular diseases frequently coexist with chronic kidney disease that constitutes a major dete...
This study was performed to assess the effect of chronic low-dose sitagliptin, a dipeptidyl peptidas...
The purpose of this paper is to evaluate the chronic effect of sitagliptin on metabolic profile, inf...